The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate

The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate

Background: Regular prophylactic therapy has become an increasingly common treatment for severe hemophilia. Therefore, hypercoagulability—a potential risk factor of thrombosis—is a cause for concern in hemophilic patients treated with a high dose of FVIII concentrate. In clot waveform analysis (CWA)...

Full description

Bibliographic Details
Main Authors: Takeshi Matsumoto, Hideo Wada, Katsuya Shiraki, Kei Suzuki, Yoshiki Yamashita, Isao Tawara, Hideto Shimpo, Motomu Shimaoka
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Journal of Clinical Medicine
Subjects:
FVIII
emicizumab
CWA
APTT
thrombin time
thrombin burst
Online Access:https://www.mdpi.com/2077-0383/12/19/6320

Internet

https://www.mdpi.com/2077-0383/12/19/6320

Similar Items